
ACIP Expands Pfizer’s RSV Vaccine Recommendation to At-Risk Adults 50–59
ACIP Expands Pfizer’s RSV Vaccine Recommendation to At-Risk Adults 50–59 Pfizer Inc. (NYSE: PFE) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to expand its recommendation for the use…













